Acceleron Pharma (XLRN) Misses Q3 EPS by 2c

Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.55), $0.02 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.08 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Oracle raises full year profit guidance, stock rises after hours
• Cosciens acquires Nualtis for up to $15M in cash deal